Malignant pleural effusion: further translational research is crucial.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Translational Lung Cancer Research

• Publication date

  2012-09-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.3978/j.issn.2218-6751.2012.09.06PMID 25806178PMCID PMC4367564
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Secreted phosphoprotein-1 directly provokes vascular leakage to foster malignant pleural effusion

  2013cited by this paper
• WITHDRAWN: Pleurodesis for malignant pleural effusions.

  2013cited by this paper
• Pleurodesis for malignant pleural effusions.

  2013cited by this paper
• Multidisciplinary management of malignant pleural effusion

  2012cited by this paper
• Antiresorptive therapies in oncology and their effects on cancer progression.

  2012cited by this paper
• What is the best treatment for malignant pleural effusions?

  2011cited by this paper
• Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

  2010cited by this paper
• Management of the patient with a malignant pleural effusion.

  2010cited by this paper
• Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study

  2010cited by this paper
• E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles

  2009cited by this paper
• Advances in the systemic therapy of malignant pleural mesothelioma

  2008cited by this paper
• A central role for tumor-derived monocyte chemoattractant protein-1 in malignant pleural effusion.

  2008cited by this paper
• Tumor Necrosis Factor-α Promotes Malignant Pleural Effusion

  2007cited by this paper
• Tumor necrosis factor-alpha promotes malignant pleural effusion.

  2007influential reference
• Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515.

  2007cited by this paper
• Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent In vivo Activity in Mesothelioma

  2007cited by this paper
• Diagnosis and management of malignant pleural effusions

  2007cited by this paper
• The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice

  2007cited by this paper
• Nuclear Factor-κB Affects Tumor Progression in a Mouse Model of Malignant Pleural Effusion

  2006cited by this paper
• Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

  2006cited by this paper
• Malignant pleural effusion, current and evolving approaches for its diagnosis and management.

  2006cited by this paper
• Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.

  2005cited by this paper
• Production of experimental malignant pleural effusions is dependent on invasion of the pleura and expression of vascular endothelial growth factor/vascular permeability factor by human lung cancer cells.

  2000cited by this paper
• Model of malignant pleural effusion of human lung adenocarcinoma in SCID mice.

  1997cited by this paper
• Experimental immunotherapy of neoplastic pleural effusion with oil-attached BCG cell-wall skeleton in mice.

  1976cited by this paper
• BCG treatment of malignant pleural effusions in the rat.

  1976cited by this paper
• Mesotheliomas in rats following inoculation with asbestos.

  1969cited by this paper

• Biobanking for Pulmonary, Critical Care, and Sleep Medicine

  2020cites this paper
• Multidisciplinary management of malignant pleural effusion

  2012cites this paper